Biohaven Ltd. Common Shares (BHVN)

It's always encouraging to get what appears to be good news from the FDA.

Biohaven stock surged early Friday after the FDA canceled an upcoming meeting to discuss the benefits and risks of its drug.

Biohaven shares rise as FDA removes advisory committee meeting for troriluzole in spinocerebellar ataxia, with decision expected in late 2025.

Merus announced a research collaboration and license agreement with Biohaven.

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.

Biohaven secures $250 million from Oberland Capital, with total cash reaching $518 million to support troriluzole launch and operations.

The company hadn't expected an advisory committee meeting, nor a three-month pushback for its rare-disease drug review.

Biohaven Ltd. (BHVN) shares rise premarket as it secures up to $600 million investment from Oberland Capital. Cash reserves expected to reach $489 million.

Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced.

Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile.

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%, down from 50.9% in January. 

The company could soon add a new, high-value treatment to its portfolio.

The DOJ announces Pfizer agreed to pay nearly $60 million to resolve false claims allegations. The SEC creates a task force dedicated to the development of a clear and comprehensive regulatory framework for crypto assets.